TScan Therapeutics (TCRX) Consolidated Net Income (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Consolidated Net Income data on file, last reported at -$28.7 million in Q1 2026.

• On a quarterly basis, Consolidated Net Income rose 22.49% year-over-year to -$28.7 million in Q1 2026; TTM through Mar 2026 was -$133.5 million, a 8.09% increase from a year earlier, with the FY2025 full-year figure at -$219.9 million, down 52.08% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$28.7 million, up from -$32.2 million in the prior quarter.
• Over the last five years, Consolidated Net Income for TCRX reached as high as -$15.1 million in Q2 2022 and fell as low as -$46.7 million in Q4 2024.
• Historically, Consolidated Net Income has averaged -$27.7 million across 5 years, with a median of -$28.7 million in 2026.
• On a YoY basis, Consolidated Net Income climbed as much as 54.13% in 2022 and fell as far as 104.2% in 2022.
• Year by year, Consolidated Net Income stood at -$19.5 million in 2022, then fell by 29.2% to -$25.3 million in 2023, then tumbled by 85.05% to -$46.7 million in 2024, then jumped by 31.13% to -$32.2 million in 2025, then climbed by 10.94% to -$28.7 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were -$28.7 million in Q1 2026, -$32.2 million in Q4 2025, and -$35.7 million in Q3 2025.